The women of No Sex for Fish are survivors — but their survival is precarious

Moderna, once the golden child of the Trump administration for its groundbreaking mRNA Covid-19 vaccine, is now facing turbulence as the political winds shift. The company, which rode high on early government support, is suddenly on shaky ground as Trump’s potential second administration signals changes to vaccine policies—leaving Moderna scrambling to adapt.

Editor’s Note: This isn’t just about one company—it’s a sign of how volatile the vaccine industry can be when politics and public health collide. Moderna’s struggles highlight the risks for biotech firms that depend heavily on government partnerships, especially when leadership changes bring new priorities. For everyday people, it raises questions about how stable our vaccine supply chain really is.

This piece dives into the latest chatter from the health care sector, spotlighting big players like Roche, ResMed, and Novartis. Think of it as a quick pulse check on how these companies are faring in the market—whether they're making gains, facing hurdles, or just holding steady. It’s the kind of insider scoop investors and industry watchers would want to skim over coffee.

Editor’s Note: For anyone tracking the health care industry—be it investors, professionals, or just the curious—this roundup offers a snapshot of where key companies stand. It’s not about groundbreaking news, but more like reading the room: Are things humming along, or is there turbulence ahead? Handy for staying in the loop without diving into dense reports.

A new study suggests that sticking to an anti-inflammatory diet—think foods like leafy greens, berries, and fatty fish—could give people with advanced colon cancer a better shot at living longer. The research, shared at a major cancer conference in Chicago, hints that what patients eat might play a bigger role in their survival than previously thought.

Editor’s Note: This isn’t just another diet trend—it’s a potential lifeline for colon cancer patients. While treatments like chemo and immunotherapy remain critical, the idea that everyday food choices could tilt the odds in their favor is huge. It’s also a reminder that science is increasingly looking at lifestyle factors as part of the cancer-fighting toolkit. For patients and families, it’s a hopeful nudge toward something they can actually control: what’s on the plate.

Health officials are urging summer camps to require measles vaccinations for kids, calling it a "ticket" to attend. The push comes as measles outbreaks spread across several provinces, with camps being advised to keep vaccination records ready in case of an infection.

Editor’s Note: Measles isn’t just a relic of the past—it’s making a comeback in some areas, and camps are being put on the front lines to help stop its spread. For parents, this means double-checking your kid’s shots before packing their sleeping bag. For everyone else, it’s a reminder that vaccines aren’t just personal choices; they’re community safeguards.

Top scientists around the world are shifting their research to countries with more stable funding as U.S. labs face deep budget cuts under the Trump administration. The article highlights how once-dominant American institutions are losing talent and momentum, while nations like Germany and China ramp up investment in critical fields like climate science and biomedical research.

Editor’s Note: This isn’t just about politics—it’s a brain drain with real consequences. When the U.S. scales back on research, breakthroughs slow down, and other countries take the lead. If you care about things like curing diseases or tackling climate change, where the money flows (or doesn’t) matters a lot.